Abstract:Purpose: Using an ensemble machine learning technique that incorporates the results of multiple machine learning algorithms, the study's objective is to build a reliable model to predict the early mortality among hepatocellular carcinoma (HCC) patients with bone metastases. Methods: We extracted a cohort of 124,770 patients with a diagnosis of hepatocellular carcinoma from the Surveillance, Epidemiology, and End Results (SEER) program and enrolled a cohort of 1897 patients who were diagnosed as having bone metastases. Patients with a survival time of 3 months or less were considered to have had early death. To compare patients with and without early mortality, subgroup analysis was used. Patients were randomly divided into two groups: a training cohort (n = 1509, 80%) and an internal testing cohort (n = 388, 20%). In the training cohort, five machine learning techniques were employed to train and optimize models for predicting early mortality, and an ensemble machine learning technique was used to generate risk probability in a way of soft voting, and it was able to combine the results from the multiply machine learning algorithms. The study employed both internal and external validations, and the key performance indicators included the area under the receiver operating characteristic curve (AUROC), Brier score, and calibration curve. Patients from two tertiary hospitals were chosen as the external testing cohorts (n = 98). Feature importance and reclassification were both operated in the study. Results: The early mortality was 55.5% (1052/1897). Eleven clinical characteristics were included as input features of machine learning models: sex (p = 0.019), marital status (p = 0.004), tumor stage (p = 0.025), node stage (p = 0.001), fibrosis score (p = 0.040), AFP level (p = 0.032), tumor size (p = 0.001), lung metastases (p < 0.001), cancer-directed surgery (p < 0.001), radiation (p < 0.001), and chemotherapy (p < 0.001). Application of the ensemble model in the internal testing population yielded an AUROC of 0.779 (95% confidence interval [CI]: 0.727–0.820), which was the largest AUROC among all models. Additionally, the ensemble model (0.191) outperformed the other five machine learning models in terms of Brier score. In terms of decision curves, the ensemble model also showed favorable clinical usefulness. External validation showed similar results; with an AUROC of 0.764 and Brier score of 0.195, the prediction performance was further improved after revision of the model. Feature importance demonstrated that the top three most crucial features were chemotherapy, radiation, and lung metastases based on the ensemble model. Reclassification of patients revealed a substantial difference in the two risk groups' actual probabilities of early mortality (74.38% vs. 31.35%, p < 0.001). Patients in the high-risk group had significantly shorter survival time than patients in the low-risk group (p < 0.001), according to the Kaplan–Meier survival curve. Conclusions: The ensemble machine learning model exhibits promising prediction performance for early mortality among HCC patients with bone metastases. With the aid of routinely accessible clinical characteristics, this model can be a trustworthy prognostic tool to predict the early death of those patients and facilitate clinical decision-making.

Establishment of prediction model for mortality risk of pancreatic cancer: a retrospective study

Prediction of 12-month recurrence of pancreatic cancer using machine learning and prognostic factors

A Prognostic Nomogram in Patients with Distant Metastasis of Pancreatic Neuroendocrine Tumors: a Population-Based Study.

Prognostic Analysis of Very Early Onset Pancreatic Cancer: a Population-Based Analysis.

Construction and Validation of Risk Factors and Prognostic Model for Liver Metastasis of Pancreatic Cancer

Development and Application of a Novel Machine Learning Model Predicting Pancreatic Cancer-Specific Mortality

A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With Acute Pancreatitis

Development and Validation of a Survival Prediction Model for Patients with Pancreatic Cancer

Predicting Postoperative Prognosis of Pancreatic Cancer Using a CT-Based Radio-Clinical Model: Exploring Biological Functions

Establishment of a prognostic model for pancreatic cancer based on mitochondrial metabolism related genes

Clinical Prediction Models for Pancreatic Cancer in General and At-Risk Populations: A Systematic Review

Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer

Survival Prediction in Pancreatic Cancer Patients with No Distant Metastasis: a Large-Scale Population-Based Estimate

Assessment of Intermediate-Term Mortality Following Pancreatectomy for Cancer

A novel prediction model of the risk of pancreatic cancer among diabetes patients using multiple clinical data and machine learning

Establishment of a Prognostic Model for Pancreatic Cancer Based on Hypoxia-Related Genes

Construction and validation of a pancreatic cancer prognostic model based on genes related to the hypoxic tumor microenvironment

Development and validation of an ensemble machine-learning model for predicting early mortality among patients with bone metastases of hepatocellular carcinoma

Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study

The Development of a Prediction Model Based on Random Survival Forest for the Postoperative Prognosis of Pancreatic Cancer: A SEER-Based Study

A predictive model for early death in elderly colorectal cancer patients: a population-based study